Related Experiment Video

Updated: Jun 26, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines

Young Mi Whang1, Kyong Hwa Park, Hae-Yun Jung

  • 1Genomic Research Center for Lung and Breast/Ovarian Cancers, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

Cancer
|January 22, 2009
PubMed
Abstract

Insights

The tumor suppressor RASSF1A enhances chemotherapy effectiveness in non-small cell lung cancer (NSCLC) by increasing sensitivity to microtubule-targeting drugs like paclitaxel and vincristine.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The tumor suppressor RASSF1A protein interacts with microtubules, inducing mitotic arrest and apoptosis.
  • Microtubule-targeting drugs paclitaxel (TXL) and vincristine (VCS) show variable efficacy in non-small cell lung cancer (NSCLC) based on microtubule-related gene status.
  • Investigating RASSF1A's role as a microtubule modulator could optimize NSCLC chemotherapy.

Purpose of the Study:

  • To determine if RASSF1A enhances sensitivity to microtubule-targeting drugs TXL and VCS in NSCLC cells.
  • To elucidate the molecular mechanisms underlying RASSF1A's effect on drug sensitivity.

Main Methods:

  • Assessed growth inhibition of RASSF1A-transfected NSCLC cells using clonogenic and flow cytometry assays.
  • Analyzed mitosis-related protein levels via Western blot and in vitro kinase assays after TXL/VCS treatment.
  • Utilized small interfering RNA (siRNA) to knockdown RASSF1A expression.

Main Results:

  • RASSF1A potentiated the growth inhibitory effects of TXL and VCS in NSCLC and bronchial epithelial cells, inducing G2/M cell cycle arrest.
  • Treated RASSF1A-transfected cells showed increased cyclin B1 and cyclin A accumulation.
  • Kinase assays confirmed RASSF1A and drug treatment inhibited cyclin B1/Cdc2 complex activity; RASSF1A knockdown reversed this.

Conclusions:

  • RASSF1A exhibits a cooperative inhibitory effect with microtubule-targeting drugs in NSCLC cells.
  • This cooperation is mediated by cyclin B1 accumulation, offering new strategies for selecting chemotherapeutic agents.

More Related Videos

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...